Skip to content
NASDAQ · MEDICINAL CHEMICALS & BOTANICAL PRODUCTS · MID CAP

Cronos Group Inc. CRON

9 fiscal years on record · USD · FY2025 reported · SEC filings only
$193.4M
▲ 19.5% YoY
$-9.4M
▼ 123.0% YoY
$149,000
▼ 97.7% YoY

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Cronos Group Inc. distributes PEACE NATURALS and LIT branded cannabis products, along with white-labeled cannabis products, to select international markets. Its international brand portfolio includes Spinach, PEACE NATURALS, LIT, and Lord Jones. As of December 31, 2025, the company had 610 full-time employees, of which 507 were in Canada, 36 were in the U.S., and 67 were in Israel. In 2025, two customers, Ontario Cannabis Retail Corporation and Alberta Gaming, Liquor and Cannabis Commission, accounted for approximately 27% and 16%, respectively, of the company's consolidated net revenues, before excise taxes, for the year. Cronos reports through one consolidated segment, which includes operations in both Canada and Israel. In Canada, the company operates a wholly owned license holder under the Cannabis Act, Peace Naturals Project Inc., which has production facilities in Stayner, Ontario known as the Peace Naturals Campus, and it also consolidates the results of Cronos GrowCo, in which it holds a 50% equity interest. In Israel, the company operates under the Good Agricultural Practices, Good Manufacturing Practices and Good Distribution Practices certifications required for the cultivation, production, distribution and marketing of medical cannabis products. Cronos is incorporated under the laws of the Province of British Columbia, with principal executive offices located at 4491 Concession Rd 12, Stayner, Ontario.

Written from the business description in Cronos Group Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 26 February 2026. Every sentence was checked against that document before publication.

Growth

USD 193.4M
Revenue, FY2025 · full 9-year series below
Revenue $B Net income $B
FY2025 · Revenue 0.2 · Net income -0.0
0.5B1.0B-0.1B-0.3B
2017202020232025
Compound annual growth
+20.9%
+28.9%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +28.9% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−2 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -11.9% · Net -2.0%
-200%-400%-600%
201720212025
ROE
FY2025 · ROE -0.9%
50%100%-10%-20%
201720212025
Three returns, three denominators.

Each USD of equity lost 1 cents this year.

Cash & shareholders

USD 9.7M
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 0.1
-100M-200M
201720212025
Net buybacks $M Dividends $M
FY2025 · Dividends · · Net buybacks 9.7
4M8M
202320242025

USD 9.7M in buybacks went back to shareholders in a year without profit.

Total assetsUSD 1.2B
EquityUSD 1.1B
CashUSD 791.8M
Current ratio19.59×

Equity funds 91% of total assets.

The 9-year record

9 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
CRON, 9-year financial record
Metric 202520242023202220212020201920182017
Revenue $B0.20.20.10.10.10.10.00.00.0
Operating income $B−0.0−0.1−0.1−0.1−0.3−0.2−0.2−0.0−0.0
EBITDA $B−0.0−0.1−0.1−0.1−0.3−0.2−0.1−0.0−0.0
Income tax $B−0.0−0.0−0.00.0−0.00.00.00.0−0.0
Net income $B−0.00.0−0.1−0.2−0.4−0.11.2−0.0−0.0
Free cash flow $B0.00.0−0.0−0.1−0.2−0.2−0.2−0.1−0.0
EPS, diluted $−0.020.11−0.19−0.45−1.07−0.213.33−0.12−0.01
Dividend / sh $◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend—————————
ROE %−0.93.8−6.6−13.6−26.0−4.2122.9−20.4−2.3
Shares out B0.380.380.380.380.370.36◌◌◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

Compare

This company against its peers

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 34 reconciliationsAUDITED

Reconciled in 9 of the 9 fiscal years we could check. 22 checks were skipped: the balance sheet is not tagged before 2018. 10 checks were skipped: EPS is not tagged before 2017.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityMedicinal Chemicals & Botanical Products
Listed onNASDAQ
Incorporated inoutside the United States — SEC code A1
Fiscal year endsDecember 31
Data on record since2017

Share this section

Download image